CAMBRIDGE, Mass., Feb. 12 /PRNewswire/ -- Mersana, a cancer therapeutics company, announced today that Timothy B. Lowinger, Ph.D., has joined the company as Chief Scientific Officer.
"We are thrilled that Tim is now a part of the Mersana team," said Julie A. Olson, President and CEO at Mersana. "His extensive leadership in oncology research and his experience with polymer-based drug systems are an ideal match for Mersana. In addition to the important impact he will have on our newest programs, his contributions toward advancing our lead product, XMT-1001, and our second product, XMT-1107, will be significant."
Dr. Lowinger has over fifteen years of experience in the pharmaceutical
industry and brings a wealth of international experience to his new role in
leading our Research team. From 1993 to 2007, Dr. Lowinger held a number of
positions at Bayer Pharmaceuticals in the US, Germany, and Japan, where he
contributed to the discovery of more than 15 pre-clinical and clinical
candidates in a variety of indications. Most notably, he led the team that
discovered and advanced Nexavar(R) (sorafenib), an anti-cancer agent that
is approved for indications including renal and hepatocellular cancer, with
Phase III studies underway in non-small-cell lung and other cancers. Later,
as the VP and Department Head of Chemistry Research in West Haven, he
managed a department of scientists in the disciplines of medicinal,
analytical, computational, combinatorial and synthetic chemistry, focused
on the discovery and clinical proof-of-concept of new therapeutics for the
treatment of cancer, diabetes and obesity. He has most recently been VP of
Chemistry and Pharmaceutical Sciences at Angiotech Pharmaceuticals where he
managed a multidisciplinary team of scientists focused on developing
polymer-based pharmaceutical products for local administration as well as
medical devices incorporating pharmaceutical agents. Dr. Lowinger has a BSc
in Chemistry and a Ph.D. in Organ
|SOURCE Mersana Therapeutics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved